| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $317,894 | 1 | 1 |
Sells | $228,564,724 | 121 | 99 |
| Caligan Partners LP | See Remarks | 1 | $317,894 | 1 | $317,894 | $0 |
| Khindri Sanjeev | Chief Development Officer | 0 | $0 | 3 | $386,708 | $-386,708 |
| Boyle Dana | Chief Accounting Officer | 0 | $0 | 11 | $2.51M | $-2.51M |
| Schundler Russell | General Counsel | 0 | $0 | 6 | $3.06M | $-3.06M |
| SINGH RAMAN | director | 0 | $0 | 4 | $3.67M | $-3.67M |
| Krepp Sarah | Chief Human Resource Officer | 0 | $0 | 9 | $3.78M | $-3.78M |
| Rielly-Gauvin Katherine | director | 0 | $0 | 2 | $4.09M | $-4.09M |
| Moomaw Scott | Chief Commercial Officer | 0 | $0 | 8 | $5.66M | $-5.66M |
| Adair Jason | Chief Business Officer | 0 | $0 | 12 | $7.91M | $-7.91M |
| Saggar Rajeev | Chief Medical Officer | 0 | $0 | 8 | $11.3M | $-11.3M |
| Manning Paul B | director | 0 | $0 | 1 | $12.78M | $-12.78M |
| Kaseta Michael | CFO and COO | 0 | $0 | 10 | $15.88M | $-15.88M |
| JEFFS ROGER | Chief Executive Officer | 0 | $0 | 26 | $32.18M | $-32.18M |
| Bloch Stephen M | director | 0 | $0 | 20 | $125.05M | $-125.05M |
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia …
Over the last 12 months, insiders at Liquidia Corporation have bought $317,894 and sold $228.56M worth of Liquidia Corporation stock.
On average, over the past 5 years, insiders at Liquidia Corporation have bought $10.22M and sold $65.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Caligan Partners LP (See Remarks) — $317,894.
The last purchase of 5,300 shares for transaction amount of $317,894 was made by Caligan Partners LP (See Remarks) on 2026‑05‑19.
| 2026-10-26 | Sale | Adair Jason | Chief Business Officer | 688 0.0008% | $43.19 | $29,715 | +2.94% | |
| 2026-10-26 | Sale | Boyle Dana | Chief Accounting Officer | 1,581 0.0018% | $43.19 | $68,283 | +2.94% | |
| 2026-10-12 | Sale | JEFFS ROGER | Chief Executive Officer | 32,744 0.0379% | $28.48 | $932,549 | +47.34% | |
| 2026-10-12 | Sale | Schundler Russell | General Counsel | 13,692 0.0159% | $28.48 | $389,948 | +47.34% | |
| 2026-10-12 | Sale | Kaseta Michael | CFO and COO | 18,938 0.0219% | $28.48 | $539,354 | +47.34% | |
| 2026-10-12 | Sale | Moomaw Scott | Chief Commercial Officer | 8,863 0.0103% | $28.48 | $252,418 | +47.34% | |
| 2026-10-12 | Sale | Adair Jason | Chief Business Officer | 7,301 0.0085% | $28.48 | $207,932 | +47.34% | |
| 2026-10-12 | Sale | Boyle Dana | Chief Accounting Officer | 5,892 0.0068% | $28.48 | $167,804 | +47.34% | |
| 2026-10-12 | Sale | Saggar Rajeev | Chief Medical Officer | 9,218 0.0107% | $28.48 | $262,529 | +47.34% | |
| 2026-10-12 | Sale | Krepp Sarah | Chief Human Resource Officer | 5,245 0.0061% | $28.48 | $149,378 | +47.34% | |
| 2026-10-12 | Sale | Khindri Sanjeev | Chief Development Officer | 1,101 0.0013% | $28.48 | $31,356 | +47.34% | |
| 2026-10-05 | Sale | Bloch Stephen M | director | 235,477 0.26% | $27.13 | $6.39M | +31.51% | |
| 2026-09-14 | Sale | SINGH RAMAN | director | 8,468 0.0097% | $66.16 | $560,243 | -35.65% | |
| 2026-09-11 | Sale | SINGH RAMAN | director | 9,024 0.0104% | $68.62 | $619,210 | -36.77% | |
| 2026-09-01 | Sale | Krepp Sarah | Chief Human Resource Officer | 274 0.0003% | $67.76 | $18,566 | -32.71% | |
| 2026-08-21 | Sale | Adair Jason | Chief Business Officer | 73,631 0.0834% | $69.09 | $5.09M | -4.82% | |
| 2026-08-20 | Sale | Rielly-Gauvin Katherine | director | 18,393 0.021% | $72.23 | $1.33M | -7.79% | |
| 2026-08-19 | Sale | Saggar Rajeev | Chief Medical Officer | 50,000 0.0553% | $74.06 | $3.7M | -12.76% | |
| 2026-08-19 | Sale | Rielly-Gauvin Katherine | director | 36,789 0.0412% | $74.99 | $2.76M | -12.76% | |
| 2026-08-17 | Sale | Saggar Rajeev | Chief Medical Officer | 29,534 0.0329% | $76.84 | $2.27M | -14.50% |
| Caligan Partners LP | See Remarks | 8138951 9.0929% | $343.46M | 3 | 2 | +56.6% |
| JEFFS ROGER | Chief Executive Officer | 1125848 1.2578% | $47.51M | 5 | 35 | +41.46% |
| Manning Paul B | director | 716311 0.8003% | $30.23M | 4 | 4 | +36.3% |
| Schundler Russell | General Counsel | 602841 0.6735% | $25.44M | 2 | 21 | +38.84% |
| Kaseta Michael | CFO and COO | 340148 0.38% | $14.35M | 2 | 27 | +33.43% |
| Moomaw Scott | Chief Commercial Officer | 181487 0.2028% | $7.66M | 1 | 28 | +17.85% |
| Bloch Stephen M | director | 0 0% | $0 | 1 | 20 | +38.27% |
| JOHNSON DAVID EDWARD | 10643627 11.8911% | $449.16M | 4 | 0 | +22.98% | |
| Canaan VIII LP | 10 percent owner | 2917169 3.2591% | $123.1M | 2 | 0 | +22.07% |
| Eshelman Ventures, LLC | 10 percent owner | 2601210 2.9061% | $109.77M | 7 | 23 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 2484870 2.7761% | $104.86M | 1 | 0 | +38.27% |
| BARRETT M JAMES | 10 percent owner | 2484870 2.7761% | $104.86M | 1 | 0 | +38.27% |
| KERINS PATRICK J | 10 percent owner | 2484870 2.7761% | $104.86M | 1 | 0 | +38.27% |
| SANDELL SCOTT D | 10 percent owner | 2484870 2.7761% | $104.86M | 1 | 0 | +38.27% |
| BASKETT FOREST | 10 percent owner | 2484870 2.7761% | $104.86M | 1 | 0 | +38.27% |
| New Enterprise Associates 12, Limited Partnership | 10 percent owner | 2484870 2.7761% | $104.86M | 1 | 0 | +38.27% |
| GLAXOSMITHKLINE PLC | Former 10% holder | 624422 0.6976% | $26.35M | 1 | 0 | +38.27% |
| Alexandria Venture Investments, LLC | 10 percent owner | 396172 0.4426% | $16.72M | 1 | 0 | +38.27% |
| Lippe Robert A | Chief Operations Officer | 193788 0.2165% | $8.18M | 2 | 4 | +47.2% |
| Kirsch Arthur S | director | 32000 0.0358% | $1.35M | 4 | 0 | <0.0001% |
| Increased Positions | 131 | +55.51% | 8M | +13.05% |
| Decreased Positions | 106 | -44.92% | 11M | -17.16% |
| New Positions | 62 | New | 3M | New |
| Sold Out Positions | 36 | Sold Out | 2M | Sold Out |
| Total Postitions | 261 | +10.59% | 62M | -4.11% |
| Farallon Capital Management Llc | $268,961.00 | 9.85% | 8.57M | +4M | +102.08% | 2025-09-30 |
| Caligan Partners Lp | $254,933.00 | 9.33% | 8.12M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $164,185.00 | 6.01% | 5.23M | +336,671 | +6.88% | 2025-09-30 |
| Vanguard Group Inc | $124,382.00 | 4.55% | 3.96M | +367,659 | +10.23% | 2025-09-30 |
| Findell Capital Management Llc | $88,862.00 | 3.25% | 2.83M | -170,000 | -5.67% | 2025-09-30 |
| Goldman Sachs Group Inc | $87,364.00 | 3.2% | 2.78M | +365,280 | +15.11% | 2025-09-30 |
| Opaleye Management Inc. | $82,111.00 | 3.01% | 2.62M | +140,000 | +5.66% | 2025-09-30 |
| State Street Corp | $60,095.00 | 2.2% | 1.91M | +83,155 | +4.54% | 2025-09-30 |
| Tcg Crossover Management, Llc | $53,697.00 | 1.97% | 1.71M | +2M | New | 2025-09-30 |
| Caprock Group, Llc | $51,248.00 | 1.88% | 1.63M | +2M | New | 2025-09-30 |